Articles by Paul G. Rubinstein

Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma

Rubinstein, Paul G.; Moore, Page C.; Rudek, Michelle A.; More

AIDS. ., Post Acceptance: December 26, 2017